抗血小板治疗对EVAR术后II型内漏相关瘤囊扩张的影响
该回顾性队列纳入EVAR术后首次随访发现II型内漏的87例患者,平均随访41.5个月。随访结束时37%患者瘤囊增长>5mm,水杨酸类治疗组瘤囊增长显著少于未治疗组(26% vs 60%,P=.004),Cox模型显示水杨酸类为保护因素(HR 0.34,95%CI 0.13-0.87,P=.024)。
要点
- EVAR术后早期II型内漏患者中,水杨酸类抗血小板治疗与瘤囊增长>5mm风险降低相关。
- 水杨酸类组瘤囊增长发生率为26%,显著低于对照组的60%(P=.004)。
- 内漏灶体积和內漏复杂性是瘤囊增长的独立危险因素。
核心结论
- EVAR术后即刻检测到II型内漏的患者中,水杨酸类抗血小板治疗与随访期间瘤囊增长>5mm风险降低相关。
- 需要基于人群的队列研究来确认该发现并指导潜在推荐。
研究设计与样本
- 回顾性分析9年期间87例EVAR术后首次随访发现II型内漏且随访至少1年的患者,平均随访41.5个月。
- 出院时50例使用水杨酸类,16例使用氯吡格雷,9例多药联合或抗凝,12例未治疗。
- 随访包括术后1、6、12个月及每年增强CT,并进行内漏三维容积测量。
主要发现
- 6个月时59%(51例)初始II型内漏持续存在。
- 随访结束时32例(37%)瘤囊增长>5mm。
- 水杨酸类组瘤囊增长发生率为26%,显著低于非水杨酸类组的60%(P=.004)。
- Cox比例风险模型显示水杨酸类为瘤囊增长的保护因素(HR 0.34,95%CI 0.13-0.87,P=.024)。
- 内漏灶体积和內漏复杂性表现为独立危险因素。
关键数值与推荐
- 瘤囊增长定义为随访结束时直径增加>5mm。
- 主要结局为6个月时内漏持续和随访结束时瘤囊增长>5mm。
临床怎么用
- 对于EVAR术后早期发现II型内漏的患者,使用水杨酸类抗血小板药物可能与较低的瘤囊增长风险相关。
- 仍需进一步研究确认该关联,暂不能据此常规推荐水杨酸类用于预防II型内漏相关的瘤囊增长。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) has gained widespread use through a solid reputation of safety and effectiveness. However, some issues, such as endoleaks and sac growth over time, still arise as important concerns. Antiplatelet therapy, mandatory as secondary prevention of cardiovascular disease, may play a role in both phenomena by interfering with blood clotting properties and the inflammatory process associated with AAA. We analyzed whether different antiplatelet therapies were independent risk factors for type II endoleak (T2E) persistence and midterm sac growth after EVAR. METHODS: All patients with T2E detected in the first post-EVAR control were included, except those without at least 1 year of complete follow-up. Data for demographics, clinical comorbidities, EVAR devices, and antiplatelet therapies were recorded. All patients underwent routine follow-up with contrast-enhanced tomography at 1 month, 6 months, 12 months, and annually thereafter. A three-dimensional rendering of each endoleak was performed for detailed volumetry. Main outcomes were endoleak persistence at 6 months and sac growth >5 mm at end of follow-up. RESULTS: During a 9-year period, 87 patients with initial T2E were monitored for a mean of 41.5 months. On discharge, salicylates were prescribed to 50, clopidogrel to 16, and multiagent therapy or anticoagulation to 9; no therapy was given to 12. No significant differences in comorbidities or baseline AAA characteristics were found between groups. At 6 months thereafter, 59% (n = 51) of the initial T2Es persisted. At end of follow-up, 32 patients had sac growth >5 mm (37%). Sac growth was significantly less frequent in the group treated with salicylates (26% vs 60%; P = .004). Cox proportional hazards model reinforced the role of salicylates as protectors for sac growth over time (hazard ratio, 0.34; 95% confidence interval, 0.13-0.87; P = .024), whereas T2E nidus volume and endoleak complexity behaved like independent risk factors. CONCLUSIONS: Antiplatelet therapy with salicylates appears to be linked to a decreased risk of sac growth >5 mm over time in patients with T2Es detected right after EVAR. Population-based cohort studies are mandatory to confirm this finding and to guide a potential recommendation.
引用
- Álvarez Marcos F, Llaneza Coto JM, Franco Meijide FJ, et al. Effect of antiplatelet therapy on aneurysmal sac expansion associated with type II endoleaks after endovascular aneurysm repair. J Vasc Surg. 2017. PMID: 28190712. doi:10.1016/j.jvs.2016.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。